126 related articles for article (PubMed ID: 20515780)
1. Biomarkers in lung cancer.
Bearz A; Berretta M; Cappellani A; Lleshi A; Berto E; Fratino L; Tirelli U
Front Biosci (Elite Ed); 2010 Jun; 2(3):1099-104. PubMed ID: 20515780
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and diagnostic usefulness of serum markers in lung cancer.
Stahel RA; Martz G
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):893-4. PubMed ID: 2822425
[No Abstract] [Full Text] [Related]
3. Serum neurone-specific enolase and other neuroendocrine markers in lung cancer.
Ledermann JA
Eur J Cancer; 1994; 30A(5):574-6. PubMed ID: 8080666
[No Abstract] [Full Text] [Related]
4. [The prescription of serum tumor markers in a general hospital].
Watine J; Charet JC; Augé MC
Presse Med; 1998 May; 27(18):862, 864. PubMed ID: 9767874
[No Abstract] [Full Text] [Related]
5. Elastase levels in small and non-small cell lung carcinoma.
Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
[No Abstract] [Full Text] [Related]
6. Evaluation of "neuron-specific enolase" as a tumor marker for small cell carcinoma of the lung.
Güner G; Oktay G; Akkoçlu A; Karlikaya C
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):306S. PubMed ID: 8224452
[No Abstract] [Full Text] [Related]
7. Serum levels of neuron-specific enolase, carbohydrate antigen 19-9 and carbohydrate antigen 125 in carcinoma of the lung.
Oktay G; Güner G; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1995 May; 23(2):211S. PubMed ID: 7672232
[No Abstract] [Full Text] [Related]
8. Tumour marker evaluation in patients with lung cancer.
Seregni E; Botti C; Bogni A; Bombardieri E
Scand J Clin Lab Invest Suppl; 1995; 221():67-71. PubMed ID: 7652492
[No Abstract] [Full Text] [Related]
9. Serum tumour markers in lung cancer.
Hansen M
Scand J Clin Lab Invest Suppl; 1991; 206():93-101. PubMed ID: 1658919
[No Abstract] [Full Text] [Related]
10. Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer.
Stieber P; Bodenmüller H; Banauch D; Hasholzner U; Dessauer A; Ofenloch-Hähnle B; Jaworek D; Fateh-Moghadam A
Clin Biochem; 1993 Aug; 26(4):301-4. PubMed ID: 7694815
[TBL] [Abstract][Full Text] [Related]
11. Letter to the Editor: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
Nicolazzo C; Raimondi C; Loreni F; Gazzaniga P; Gradilone A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629196
[TBL] [Abstract][Full Text] [Related]
12. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.
Köhler J; Schuler M; Gauler TC; Nöpel-Dünnebacke S; Ahrens M; Hoffmann AC; Kasper S; Nensa F; Gomez B; Hahnemann M; Breitenbuecher F; Cheufou D; Özkan F; Darwiche K; Hoiczyk M; Reis H; Welter S; Eberhardt WE; Eisenacher M; Teschler H; Stamatis G; Schmiegel W; Hahn SA; Baraniskin A
J Cancer Res Clin Oncol; 2016 Apr; 142(4):795-805. PubMed ID: 26687686
[TBL] [Abstract][Full Text] [Related]
13. Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
Alama A; Coco S; Vanni I; Grossi F
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629197
[TBL] [Abstract][Full Text] [Related]
14. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.
Cobos E; Jumper C; Lox C
Clin Appl Thromb Hemost; 2003 Jul; 9(3):241-6. PubMed ID: 14507113
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of plasma D-dimer levels in patients with lung cancer.
Taguchi O; Gabazza EC; Yasui H; Kobayashi T; Yoshida M; Kobayashi H
Thorax; 1997 Jun; 52(6):563-5. PubMed ID: 9227726
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis.
Ueno K; Inoue Y; Kawaguchi T; Hosoe S; Kawahara M
Lung Cancer; 2001; 31(2-3):213-9. PubMed ID: 11165400
[TBL] [Abstract][Full Text] [Related]
18. c-erbB-2 protein in serum of primary lung cancer patients.
Filiberti R; Marroni P; Paganuzzi M; Izzo V; Padovani P; Cafferata M; Ardizzoni A; Neri M; Raimondi L; Puntoni R
Cancer Detect Prev; 2002; 26(1):64-8. PubMed ID: 12088205
[TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
20. Factors confounding evaluation of treatment effect in lung cancer.
Osterlind K
Lung Cancer; 1994 Mar; 10 Suppl 1():S97-103. PubMed ID: 8087532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
